The E Selectin pipeline drugs market research report outlays comprehensive information on the E Selectin targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the E Selectin pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Oncology, Hematological Disorders, and Gastrointestinal which include the indications Critical Limb Ischemia, Atherosclerosis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Metastatic Lung Cancer, Sickle Cell Disease With Vaso-Occlusive Crisis, and Hepatic Injury. It also reviews key players involved in E Selectin targeted therapeutics development with respective active and dormant or discontinued products.
The E Selectin pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, and Preclinical stages are 1, 1, and 4 respectively.
E Selectin overview
Selectin E is a protein that in humans is encoded by a gene SELE. It is found in cytokine-stimulated endothelial cells and is responsible for the accumulation of blood leukocytes at sites of inflammation by mediating the adhesion of cells to the vascular lining. These proteins are part of the selectin family of cell adhesion molecules. Adhesion molecules participate in the interaction between leukocytes and the endothelium and appear to be involved in the pathogenesis of atherosclerosis.
For a complete picture of E Selectin’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
